Abstract
Background: Primary aldosteronism is the most common causes of secondary hypertension. Patients suffering from this clinical syndrome have an increased cardiovascular risk and target organ damage. Mineralocorticoid receptor antagonists are the optimal pharmaceutical option for the management of such patients.
Objectives: The study aimed to assess the effects of mineralocorticoid receptor antagonist in the treatment of patients with primary aldosteronism.
Method: We conducted an in-depth review of the literature and comprehensive identification of the clinical studies investigating the efficacy of mineralocorticoid receptor antagonists in individuals with primary aldosteronism.
Results: Mineralocorticoid receptor antagonists result in significant improvement in blood pressure and serum potassium level among patients with primary aldosteronism. Moreover, mineralocorticoid receptor antagonists reverse left ventricular hypertrophy, albuminuria, and carotid intima-media thickness. However, a high risk for atrial fibrillation remains among subject with primary aldosteronism in such agents.
Conclusion: Mineralocorticoid receptor antagonists are recommended as the first-line treatment in patients with bilateral primary aldosteronism. In patients with unilateral aldosterone-producing adenoma, adrenalectomy should be preferred. However, existing data presents significant limitations and is rather inconclusive. Future randomized control trials are required in order to illustrate the field.
Keywords: Primary aldosteronism, secondary hypertension, mineralocorticoid receptor antagonist, spironolactone, eplerenone, cardiovascular risk, target-organ damage.
[1]
Conn JW, Part I. Painting background. Part II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955; 45: 3-17.
[2]
Funder JW. Aldosterone and mineralocorticoid receptors-physiology and pathophysiology. Int J Mol Sci 2017; 18: E1032.
[3]
Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89: 1045-50.
[4]
Faselis C, Doumas M, Papademetriou V. Common secondary causes of resistant hypertension and rational for treatment. Int J Hypertens 2011; 2011: 236239.
[5]
Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101: 1889-916.
[6]
Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293-300.
[7]
Douma S, Petidis K, Doumas M, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008; 371: 1921-6.
[8]
Käyser SC, Dekkers T, Groenewoud HJ, et al. Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. J Clin Endocrinol Metab 2016; 101: 2826-35.
[9]
Maiolino G, Rossitto G, Bisogni V, et al. Quantitative Value of Aldosterone-Renin Ratio for Detection of Aldosterone-Producing Adenoma: The Aldosterone-Renin Ratio for Primary Aldosteronism (AQUARR) Study. J Am Heart Assoc 2017; 6: e005574.
[10]
Monticone S, Burrello J, Tizzani D, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in Primary Care Practice. J Am Coll Cardiol 2017; 69: 1811-20.
[11]
Savard S, Amar L, Plouin PF, et al. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension 2013; 62: 331-6.
[12]
Monticone S, D’Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2018; 6: 41-50.
[13]
Doumas M, Douma S. Primary aldosteronism: a field on the move.In: Tsioufis C, Schmieder R, Mancia G, eds Interventional Therapies for Secondary and Essential Hypertension, Updates in Hypertension and Cardiovascular Protection. Cham, Switzerland: Springer International Publishing 2016; pp. 26-55.
[14]
Doumas M, Athyros V, Papademetriou V. Screening for primary aldosteronism: whom and how? J Clin Hypertens (Greenwich) 2015; 17: 547-8.
[15]
Stavropoulos K, Imprialos KP, Doumas M. Bypass of confirmatory tests for case detection of primary aldosteronism in leaner patients? J Clin Hypertens (Greenwich) 2017; 19: 798-800.
[16]
Wolley MJ, Stowasser M. New advances in the diagnostic workup of primary aldosteronism. J Endocr Soc 2017; 1: 149-61.
[17]
Nishikawa T, Omura M, Satoh F, et al. Guidelines for the diagnosis and treatment of primary aldosteronism-the Japan Endocrine Society 2009. Endocr J 2011; 58: 711-21.
[18]
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018; 71: e127-248.
[19]
Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-357.
[20]
Stavropoulos K, Imprialos KP, Katsiki N, et al. Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone? J Clin Hypertens (Greenwich) 2018; 20: 942-8.
[21]
Williams TA, Reincke M. MANAGEMENT OF ENDOCRINE DISEASE: Diagnosis and Management of Primary Aldosteronism: the Endocrine Society guideline 2016 revisited. Eur J Endocrinol 2018. pii: EJE-17-0990
[22]
Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2016; 175: G1-G34.
[23]
Amar L, Baguet JP, Bardet S, et al. SFE/SFHTA/AFCE primary aldosteronism consensus: introduction and handbook. Ann Endocrinol (Paris) 2016; 77: 179-86.
[24]
Doumas M, Athyros V, Papademetriou V. Screening for primary aldosteronism: whom and how? J Clin Hypertens (Greenwich) 2015; 17: 547-8.
[25]
Young WF, Stanson AW, Thompson GB, et al. Role for adrenal venous sampling in ptimary aldosteronism. Surgery 2004; 136: 1227-35.
[26]
Patel SM, Lingam RK, Beaconsfield TI, et al. Role of radiology in the management of primary aldosteronism. Radiographics 2007; 27: 1145-57.
[27]
Kempers MJ, Lenders JW, van Outheusden L, et al. Systematic review: diagnostic procedure to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med 2009; 151: 329-37.
[28]
Raman SP, Lessne M, Kawamoto S, et al. Diagnostic performance of multidetector computed tomography in distinguishing unilateral from bilateral abnormalities in primary hyperaldosteronism: comparison of multidetector computed tomography with adrenal vein sampling. J Comput Assist Tomogr 2015; 39: 414-8.
[29]
Deinum J, Prejbisz A, Lenders JWM, et al. Adrenal Vein Sampling Is the Preferred Method to Select Patients With Primary Aldosteronism for Adrenalectomy: Con Side of the Argument. Hypertension 2018; 71: 10-4.
[30]
Williams TA, Burrello J, Sechi LA, et al. Computed tomography and adrenal venous sampling in the diagnosis of unilateral primary aldosteronism. Hypertension 2018; 82: 641-9.
[31]
Rossi GD, Auchus RJ, Brown M, et al. An Expert Consensus Statement on Use of Adrenal Vein Sampling for the Subtyping of Primary Aldosteronism. Hypertension 2014; 63: 151-60.
[32]
Rossi GP, Funder JW. Adrenal Vein Sampling Is the Preferred Method to Select Patients With Primary Aldosteronism for Adrenalectomy: Pro Side of the Argument. Hypertension 2018; 71: 5-9.
[33]
Rossi GP. Update in adrenal venous sampling for primary aldosteronism. Curr Opin Endocrinol Diabetes Obes 2018; 25: 160-71.
[34]
Heinze B, Fuss CT, Mulatero P, et al. Targeting CXCR4 (CXC Chemokine Receptor Type 4) for molecular imaging of aldosterone-producing adenoma. Hypertension 2018; 71: 317-25.
[35]
Seccia TM, Caroccia B, Adler GK, et al. Arterial hypertension, atrial fibrillation, and hyperaldosteronism: the triple trouble. Hypertension 2017; 69: 545-50.
[36]
Gaddam K, Corros C, Primenta E, et al. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patient with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension 2010; 55: 11-37.
[37]
Chen ZW, Huang KC, Lee JK, et al. Aldosterone induces left ventricular subclinical systolic dysfunction: a strain imaging study. J Hypertens 2018; 36: 353-60.
[38]
Rizzoni D, Paiardi S, Rodella L, et al. Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism. J Clin Endocrinol Metab 2006; 91: 2638-42.
[39]
Rossi GP, Cesari M, Pessina AC. Left ventricular changes in primary aldosteronism. Am J Hypertens 2003; 16: 96-8.
[40]
Pimenta E, Gordon RD, Ahmed AH, et al. Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case-control study. J Clin Endocrinol Metab 2011; 96: 2813-20.
[41]
Muiesan ML, Salvetti M, Paini A, et al. Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension 2008; 52: 529-34.
[42]
Bernini G, Galetta F, Franzoni F, et al. Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism. J Hypertens 2008; 26: 2399-405.
[43]
Holaj R, Zelinka T, Wichterle D, et al. Increased intima-media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension. J Hypertens 2007; 25: 1451-7.
[44]
Tsuchiya K, Yoshimoto T, Hirata Y. Endothelial dysfunction is related to aldosterone excess and raised blood pressure. Endocr J 2009; 56: 533-9.
[45]
Calhoun DA. Medical versus surgical treatment of primary aldosteronism. Hypertension 2018; 71: 566-8.
[46]
Amar L, Lorthioir A, Azizi M, et al. Progress in primary aldosteronism. Mineralocorticoid antagonist treatment for aldosterone-producing adenoma. Eur J Endocrinol 2015; 172: R125-9.
[47]
Fischer E, Hanslik G, Pallauf A, et al. Prolonged zona glomerulosa insufficiency causing hyperkalemia in primary aldosteronism after adrenalectomy. J Clin Endocrinol Metab 2012; 97: 3965-73.
[48]
Prada ETA, Burrello J, Reincke M, et al. Old and new concepts in the molecular pathogenesis of primary aldosteronism. Hypertension 2017; 70: 875-81.
[49]
Fischer E, Beuschlein F, Degenhart C, et al. Spontaneous remission of idiopathic aldosteronism after long-term treatment with spironolactone: results from the German Conn’s Registry. Clin Endocrinol (Oxf) 2012; 76: 473-7.
[50]
Armanini D, Fiore C, Pellati D. Spontaneous resolution of idiopathic aldosteronism after long-term treatment with potassium canrenoate. Hypertension 2007; 50: e69-70.
[51]
Yoneda T, Demura M, Takata H, et al. Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy. J Clin Endocrinol Metab 2012; 97: 1109-13.
[52]
Sukor N, Kogovsek C, Gordon RD, et al. Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism. J Clin Endocrinol Metab 2010; 95: 1360-4.
[53]
Künzel HE, Apostolopoulou K, Pallauf A, et al. Quality of life in patients with primary aldosteronism: Gender differences in untreated and long-term treated patients and associations with treatment and aldosterone. J Psychiatr Res 2012; 46: 1650-4.
[54]
Riester A, Reincke M. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy. Eur J Endocrinol 2015; 172: R23-30.
[55]
Stavropoulos K, Sotiriadis A, Patoulias D, et al. Pseudohyperaldosteronism due to mumijo consumption during pregnancy: a licorise-like syndrome. Gynecol Endocrinol 2018; 34(12): 1091-21.
[56]
Jeunemaitre X, Chatellier G, Kreft-Jais C, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987; 60: 820-5.
[57]
Sica DA. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 2005; 10: 23-9.
[58]
Faselis C, Boutari C, Doumas M, et al. Novel drugs for hypertension and heart failure: struggling for a place under the sum. Curr Pharm Des 2017; 23: 1540-50.
[59]
Hundemer GL, Curhan GC, Yozamp N, et al. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol 2018; 6: 51-9.
[60]
Wu VC, Wang SM, Chang CH, et al. Long term outcome of aldosteronism after target treatments. Sci Rep 2016; 6: 32103.
[61]
Catena C, Colussi G, Nadalini E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 80-5.
[62]
Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386: 2059-68.
[63]
Brown JJ, Davies DL, Ferriss JB, et al. Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin. BMJ 1972; 2: 729-34.
[64]
Horky K, Widimsky J Jr, Hradec E, et al. Long-term results of surgical and conservative treatment of patients with primary aldosteronism. Exp Clin Endocrinol 1987; 90: 337-46.
[65]
Karagiannis A. Treatment of primary aldosteronism: were are we now? Rev Endocr Metab Disord 2011; 12: 15-20.
[66]
Funder JW. Primary aldosteronism: are we missing the wood for the trees? Horm Metab Res 2012; 44: 251-3.
[67]
Lim PO, Jung RT, MacDonald TM. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol 1999; 48: 756-60.
[68]
Karagiannis A, Tziomalos K, Kakafika AI, et al. Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas. Endocr Relat Cancer 2008; 15: 693-700.
[69]
Muth A, Ragnarsson O, Johannsson G, et al. Systematic review of surgery and outcomes in patients with primary aldosteronism. Br J Surg 2015; 102: 307-17.
[70]
Benham JL, Eldoma M, Khokhar B, et al. Proportion of patients with hypertension resolution following adrenalectomy for primary aldosteronism: a systematic review and meta-analysis. J Clin Hypertens (Greenwich) 2016; 18: 1205-12.
[71]
Catena C, Colussi G, Lapenna R, et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007; 50: 911-8.
[72]
Rossi GP, Cesari M, Cuspidi C, et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension 2013; 62: 62-9.
[73]
Indra T, Holaj R, Strauch B, et al. Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2015; 16: 1109-17.
[74]
Park KS, Kim JH, Yang YS, et al. Outcomes analysis of surgical and medical treatments for patients with primary aldosteronism. Endocr J 2017; 64: 623-32.
[75]
Karagiannis A, Tziomalos K, Papageorgiou A, et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Exp Opin Pharmacotheur 2008; 9: 509-15.
[76]
Karashima A, Yoneda T, Kometani M, et al. Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism. Hypertens Res 2016; 39: 133-7.
[77]
Parthasarathy HK, Ménard J, White WB, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 2011; 29: 980-90.
[78]
Ori Y, Chagnac A, Korzets A, et al. Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low dose spironolactone. Nephrol Dial Transplant 2013; 28: 1787-93.
[79]
Bernini G, Bacca A, Carli V, et al. Cardiovascular changes in patients with primary aldosteronism after surgical or medical treatment. J Endocrinol Invest 2012; 35: 274-80.
[80]
Muiesan ML, Salvetti M, Paini A, et al. Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension 2008; 52: 529-34.
[81]
Marzano L, Colussi G, Sechi LA, et al. Adrenalectomy is comparable with medical treatment for reduction of left ventricular mass in primary aldosteronism: meta-analysis of long-term studies. Am J Hypertens 2015; 28: 312-8.
[82]
Rossi GP, Maiolino G, Flego A, Wang M, Vaidya A, et al. Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term. Hypertension 2018; 71: 585-91.
[83]
Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism. JAMA Cardiol 2018; 3(8): 768-74.
[84]
Rossi GP, Bernini G, Desideri G, et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006; 48: 232-8.
[85]
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3(1): 1-150.
[86]
Sechi LA, Novello M, Lapenna R, et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006; 295: 2638-45.
[87]
Sechi LA, Di Fabio A, Bazzocchi M, et al. Intrarenal hemodynamics in primary aldosteronism before and after treatment. J Clin Endocrinol Metab 2009; 94: 1191-7.
[88]
Nakano Y, Yoshimoto T, Fukuda T, et al. Effect of eplerenone on the glomerular filtration rate (GFR) in primary aldosteronism: sequential changes in the GFR during preoperative eplerenone treatment to subsequent adrenalectomy. Intern Med 2018; 57(17): 2459-66.
[89]
Fourkiotis V, Vonend O, Diederich S, et al. Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. Eur J Endocrinol 2012; 168: 75-81.
[90]
Steichen O, Lothioir A, Zinzindohoue F, et al. Outcomes of drug-based and surgical treatments for primary aldosteronism. Adv Chronic Kidney Dis 2015; 22: 196-203.
[91]
Brown JM, Robinson-Cohen C, Luque-Fernandez MA, et al. The spectrum of subclinical primary aldosteronism and incident hypertension: a cohort study. Ann Intern Med 2017; 167: 630-41.
[92]
Stavropoulos K, Imprialos KP, Doumas M, et al. Carotid intima-media thickness as a target-organ damage and treatment-target: need for a major revision? J Clin Hypertens (Greenwich) 2018; 20: 255-7.
[93]
Widimsky J Jr, Strauch B, Petrak O, et al. Vascular disturbances in primary aldosteronism: clinical evidence. Kidney Blood Press Res 2012; 35: 529-33.
[94]
Strauch B, Petrak O, Wichterle D, et al. Increased wall stiffness in primary aldosteronism in comparison with essential hypertension. Am J Hypertens 2006; 19: 909-14.
[95]
Rizzoni D, Paiardi S, Rodella L, et al. Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism. J Clin Endocrinol Metab 2006; 91: 2638-42.
[96]
Matsuda Y, Kawate H, Matsuzaki C, et al. Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism. Endocr J 2016; 63: 249-55.
[97]
Holaj R, Rosa J, Zelinka T, et al. Long-term effect of specific treatment of primary aldosteronism carotid intima-media thickness. J Hypertens 2015; 33: 874-82.
[98]
NCT02885662. Study of CS-3150 in patients with primary aldosteronism. Available at URL: https: //clinicaltrials.gov/ct2/ show/NCT02885662
Related Journals
Current Drug Safety
Current Medicinal Chemistry
Current Neuropharmacology
Current Pharmaceutical Analysis
Current Topics in Medicinal Chemistry
Current Vascular Pharmacology
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
CNS & Neurological Disorders - Drug Targets
Related Books
New Findings from Natural Substances
Mitochondrial DNA and the Immuno-inflammatory Response: New Frontiers to Control Specific Microbial Diseases
Pharmaceutical Chemistry and Production: An Introductory Textbook
Evidence-Based Research in Ayurveda against COVID-19 in Compliance with Standardized Protocols and Practices
Frontiers in Clinical Drug Research – Anti Allergy Agents
Pharmaceuticals for Targeting Coronaviruses
Medical Applications of Beta-Glucan
Nanotechnology Driven Herbal Medicine for Burns: From Concept to Application
Postbiotics: Science, Technology and Applications
Frontiers in Inflammation
Article Metrics
63
4
1
1